Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges

被引:23
作者
Dimas, Grigorios G. [1 ]
Didangelos, Triantafyllos P. [1 ]
Grekas, Dimitrios M. [1 ]
机构
[1] Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Med Sch, Propaedeut Med Dept Internal Med 1, Thessaloniki, Greece
关键词
Matrix metalloproteinases; gelatinases; diabetic nephropathy; atherosclerosis; proteinuria; glomerulosclerosis; MESSENGER-RNA EXPRESSION; URIC-ACID LEVELS; KIDNEY-DISEASE; ARTERIOVENOUS-FISTULA; EXTRACELLULAR-MATRIX; TISSUE INHIBITORS; CAROTID-ARTERY; RENAL-FUNCTION; GROWTH-FACTOR; METALLOPROTEINASES;
D O I
10.2174/1570161115666170202162345
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Matrix metalloproteinases (MMPs) are zinc-dependent proteases that degrade components of the extracellular matrix (ECM). In glomerular disease, MMPs are major regulators of ECM degradation as well as structural and functional integrity in the glomerulus. In altered matrix composition diseases, glomerular damage is due to increased degradation of kidney and vessel basement membranes (BMs) by MMPs. MMP -2 and -9 are both considered as the main enzymes that degrade collagen type-IV (coll-IV), which represents the key collagenous component of ECM and constitutes the architectural structure of vessels and glomerular BM. There is growing evidence implicating MMPs in atherosclerosis as well as in cardiovascular disease (CVD) and chronic kidney disease (CKD). Specific endogenous tissue inhibitors of MMPs (TIMPs) are also implicated in CKD, CVD and diabetic nephropathy (DN). Conclusion: The present review discusses the role of MMPs -2 and -9 in DN, as a leading cause of endstage renal disease and as a model of the link between progressive glomerulosclerosis and MMP expression.
引用
收藏
页码:557 / 565
页数:9
相关论文
共 89 条
[1]   The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis [J].
Abilleira, Sonia ;
Bevan, Steve ;
Markus, Hugh S. .
JOURNAL OF MEDICAL GENETICS, 2006, 43 (12) :897-901
[2]   Localization of matrix metalloproteinases and their inhibitors in experimental progressive kidney scarring [J].
Ahmed, A. K. ;
Haylor, J. L. ;
El Nahas, A. M. ;
Johnson, T. S. .
KIDNEY INTERNATIONAL, 2007, 71 (08) :755-763
[3]   Increasing arteriovenous fistulas in hemodialysis patients: Problems and solutions [J].
Allon, M ;
Robbin, ML .
KIDNEY INTERNATIONAL, 2002, 62 (04) :1109-1124
[4]   Simvastatin Therapy Decreases MMP-9 Levels in Obese Women [J].
Andrade, Vanessa Leite ;
do Valle, Izabella Batistelli ;
Sandrim, Valeria Cristina .
JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (10) :1072-1077
[5]   Local delivery of matrix metalloproteinase gene prevents the onset of renal sclerosis in streptozotocin-induced diabetic mice [J].
Aoyama, T ;
Yamamoto, S ;
Kanematsu, A ;
Ogawa, O ;
Tabata, Y .
TISSUE ENGINEERING, 2003, 9 (06) :1289-1299
[6]   MMP9 Limits Apoptosis and Stimulates Branching Morphogenesis During Kidney Development [J].
Arnould, Catherine ;
Lelievre-Pegorier, Martine ;
Ronco, Pierre ;
Lelongt, Brigitte .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (10) :2171-2180
[7]   Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome - A subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study [J].
Athyros, Vasilios G. ;
Mikhailidis, Dimitri P. ;
Liberopoulos, Evangelos N. ;
Kakafika, Anna I. ;
Karagiannis, Asterios ;
Papageorgiou, Athanasios A. ;
Tziomalos, Konstantinos ;
Ganotakis, Emmanuel S. ;
Elisaf, Moses .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (01) :118-127
[8]   Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study [J].
Athyros, Vassilios G. ;
Karagiannis, Asterios ;
Ganotakis, Emmanouel S. ;
Paletas, Konstantinos ;
Nicolaou, Vassilios ;
Bacharoudis, George ;
Tziomalos, Konstantinos ;
Alexandrides, Theodore ;
Liberopoulos, Evangelos N. ;
Mikhailidis, Dimitri P. .
CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (08) :1659-1668
[9]   Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? [J].
Athyrost, Vasilios G. ;
Katsiki, Niki ;
Karagiannis, Asterios ;
Mikhailidis, Dimitri P. .
EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (10) :1449-1461
[10]   Flow regulation of 72-kD collagenase IV (MMP-2) after experimental arterial injury [J].
Bassiouny, HS ;
Song, RH ;
Hong, XF ;
Singh, A ;
Kocharyan, H ;
Glagov, S .
CIRCULATION, 1998, 98 (02) :157-163